Real‐world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer

Abstract

Docetaxel chemotherapy in hormone-naïve mPC has significant toxicities, but has a similar effect on time to progression and overall survival as seen in randomised trials. Chemotherapy should be started at ≥3 weeks after ADT.